VPT:CC - Ventripoint Announces Changes to The Board of Directors
(TheNewswire)
Toronto, Ontario – February 13,2024 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), ( TSXV:VPT ) ( OTCVPTDF ) announces changes to the Board of Directors.
With the recent appointment of Hugh MacNaught asInterim CEO and President, the composition ofboard committees has been adjusted as follows: .
Nominating and Corporate Governance Committee: Dr.George Adams (chair), Robert Hodgkinson, Hugh MacNaught
Compensation Committee: Fiona Fitzgerald, RandyAucoin
Audit Committee: Robert Hodgkinson (chair), RandyAuCoin, George Adams,
Further, Dr. Alvira Macanovic has resigned as adirector of the Company effective February 12, 2024. The Companythanks her for her service and wishes her success in her futureendeavors.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release .
Copyright (c) 2024 TheNewswire - All rights reserved.